Contract research organization Clinlogix recently signed agreements with separate companies to conduct clinical research on two new, emerging technologies in class III cardiovascular medical devices.
Under the agreements, Clinlogix will work directly with KOLs and clinical sites alongside the companies on trial design, patient recruitment, trial monitoring and data collection to help shepherd these novel technologies to market.
Companies that select Clinlogix cite its strong ties and reputation with clinical sites and strengths in study design, patient recruitment and site monitoring among the top reasons to work with the CRO.
Clinical sites also recognize the value and expertise of the Clinlogix staff, recently voting it the best CRO for Site Monitoring in a survey conducted by Nice Insight.
"We believe the key to the success of any project is teaming with our client to secure the right clinical site with access to the right patients," says JeanMarie Markham, Clinlogix CEO.
"Because of the quality of the data and supporting documents we produce, our customers tell us they have received higher value in licensing deals, or have increased the overall value of their companies."
Clinlogix has deep institutional expertise running clinical research in the areas of cardiovascular diseases, endovascular diseases, diabetes, biology, neurology and oncology in medical devices. Its deep ties to experts in these fields has created a strong referral network for new business and the ability to pair scientific leadership with executional excellence.
Clinlogix is a global clinical research organization that delivers individualized clinical research solutions to the medical device and biopharmaceutical industries.
Its full suite of services support clinical development of medical devices, pharmaceuticals, biologics and diagnostics from early feasibility/discovery through first-in-human, feasibility, pivotal and post-market clinical studies.